International reference: 3 US FDA recalls for this ingredient

Subpotent Drug: Formulated amount of sennosides component is less than labelled claim. (component)

Chemical Contamination: The product may contain trace amounts of benzophenone, a component of the label varnish that may leach through the bottle and into the drug product. (component)

Lack of Assurance of Sterility: Potential presence of leaks originating from the Luer component. (component)

US-market enforcement records (OpenFDA), shown for reference - not specific to this product in Zimbabwe.

PHARMACY MEDICINES (P.) Zimbabwe · MCAZ

ACID COMPONENT HAEMODIALYSIS CONCENTRATE

ACID COMPONENT HAEMODIALYSIS CONCENTRATE

92/23.3.2/2616 SOLUTION 210.7; 5.22; 3.56; 9; 6.31G

What it does

This medicine is used to treat various health conditions.

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
92/23.3.2/2616
Registration date
1992-04-22
Expiry date
2027-12-31
Status
PHARMACY MEDICINES (P.)
Active ingredient
ACID COMPONENT HAEMODIALYSIS CONCENTRATE
Dosage form
SOLUTION
Strength
210.7; 5.22; 3.56; 9; 6.31G
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Datlabs
Applicant / LTR
DATLABS PRIVATE LIMITED
Country of origin
-
Manufacturer location
45 Falcon St, Bulawayo, Zimbabwe

Source: Medicines Control Authority of Zimbabwe · fetched 2026-04-18 08:22:04 · updated 2026-07-12 04:30:03

Disclaimer: This information is sourced from Medicines Control Authority of Zimbabwe (Zimbabwe). Always consult a qualified healthcare professional before using any medication.

About component

This medicine is used to treat various health conditions.

How it works

This medicine works by having a specific effect on the body to help improve health.

Who it's for

This medicine is suitable for people with certain health conditions as prescribed by a healthcare professional.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

About haemodialysis

Haemodialysis is a medical procedure that helps remove waste products and excess fluid from the blood when the kidneys are not working properly.

What it treats

  • kidney failure (renal failure)
  • severe kidney disease

How it works

During haemodialysis, a machine filters your blood to remove harmful substances and extra fluids, helping to keep your body in balance.

Who it's for

It is for people with kidney problems who cannot filter their blood effectively on their own.

Cautions

  • • This procedure needs to be performed by trained healthcare professionals.
  • • It may not be suitable for everyone, depending on individual health conditions.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: component

Component is a term often used to refer to a part of a combination product, such as a drug that is part of a multi-ingredient formulation. The specific pharmacological profile, uses, and properties of a component can vary significantly depending on the context of its use and the other ingredients it is combined with. Generally, components can act through various mechanisms, including receptor interaction, enzyme inhibition, or modulation of physiological pathways.

Dosage

Children: Refer to the BNF for Children for appropriate dosing information.

Adults: Refer to specific product guidelines and the BNF for appropriate dosing information.

Mechanism of action

The mechanism of action for a component depends on its individual pharmacological characteristics. Components may act as agonists or antagonists at specific receptors, inhibit or enhance enzyme activity, or modulate neurotransmitter levels. For example, some components may increase the availability of a neurotransmitter at synapses, thereby enhancing or inhibiting certain physiological responses.

Pharmacodynamics

Pharmacodynamics of a component involves the study of its effects on the body, including its therapeutic effects, side effects, and the relationship between drug concentration and effect. The efficacy of a component can be influenced by the presence of other ingredients in a formulation, as well as by individual patient factors such as age, weight, and genetic makeup. The therapeutic window of components can vary, necessitating careful monitoring to avoid toxicity.

Pharmacokinetics

Pharmacokinetics refers to the absorption, distribution, metabolism, and excretion (ADME) of a component. The bioavailability of a component can be affected by its formulation, route of administration, and the presence of food. Components may be metabolized in the liver or other tissues, and their elimination can occur via the kidneys or other pathways. The half-life and clearance rates of components are essential for determining dosing intervals and potential accumulation in the body.

Pregnancy

Consult a healthcare provider as safety in pregnancy varies with specific components.

Breast-feeding

Consult a healthcare provider as safety in breastfeeding varies with specific components.

Storage

Store in a cool, dry place away from direct sunlight.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Clinical monograph: haemodialysis

Haemodialysis is a medical procedure used to remove waste products and excess fluid from the blood when the kidneys are not functioning properly. It is primarily used in patients with end-stage renal disease or acute kidney injury. The process involves circulating the patient's blood through a dialyzer, which acts as an artificial kidney, allowing for the filtration of toxins and excess substances while retaining necessary components such as blood cells and proteins.

Indications

  • End-stage renal disease
  • Acute kidney injury
  • Severe electrolyte imbalances (e.g., hyperkalemia)
  • Toxin removal in cases of overdose or poisoning (e.g., salicylates, lithium)
  • Fluid overload that is unresponsive to diuretics

Dosage

Children: In children, haemodialysis is also individualized based

Adults: The dosage and frequency of haemodialysis depend on individual patient needs, typically ranging from 3 to 5 sessions per week, with each session lasting about 3 to 5 hours.

Mechanism of action

Haemodialysis operates by the principles of diffusion and ultrafiltration. During the procedure, blood is drawn from the patient and passed through a dialyzer, where it encounters a semi-permeable membrane. Waste products and excess electrolytes diffuse from the blood into a dialysis solution (dialysate) that is flowing on the other side of the membrane, effectively cleaning the blood. The ultrafiltration process allows for the removal of excess fluid based on pressure gradients.

Pharmacodynamics

Haemodialysis effectively reduces levels of urea, creatinine, and other solutes in the blood, improves electrolyte balance, and alleviates symptoms of fluid overload such as hypertension and pulmonary congestion. It can also help correct metabolic acidosis and restore normal acid-base balance in patients with impaired renal function.

Pharmacokinetics

Haemodialysis does not have traditional pharmacokinetics as it is a dialysis procedure rather than a drug. However, the removal rates of various solutes depend on factors such as their molecular size, the dialyzer's surface area, blood and dialysate flow rates, and the duration of the treatment. The clearance of substances during haemodialysis can be quantified, allowing for adjustments in treatment protocols to optimize patient outcomes.

Adverse effects

  • Hypotension
  • Muscle cramps
  • Nausea
  • Headache
  • Fatigue
  • Infection at the access site
  • Electrolyte imbalances

Precautions

  • Monitor for signs of infection at the access site
  • Assess blood pressure regularly during treatment
  • Be cautious in patients with cardiovascular disease
  • Evaluate electrolyte levels frequently

Pregnancy

Safety during pregnancy has not been established. Use only if clearly needed.

Breast-feeding

Safety during breastfeeding is not established. Consult a healthcare provider.

Storage

No specific storage requirements as it is performed in a clinical setting.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.